Your session is about to expire
← Back to Search
Magrolimab + Pembrolizumab for Hodgkin's Lymphoma
Study Summary
This trial will test if magrolimab, when combined with pembrolizumab, is safe and effective in treating patients with Hodgkin lymphoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 1 & 2 trial • 78 Patients • NCT02953782Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am fully active or restricted in physically strenuous activity but can do light work.I have undergone at least two different treatments for my condition.I have had a stem cell transplant from a donor.I am fully active or restricted in physically strenuous activity but can do light work.I am a man who can father children and will use contraception during and 4 months after the study.I have had another cancer, but it has been in complete remission for at least a year, except for skin cancer or localized prostate cancer.I haven't had hemolytic anemia, autoimmune thrombocytopenia, or Evan's syndrome in the last 3 months.I have not taken PD-1 inhibitors in the last 6 months.My white blood cell count is healthy without needing medication.I have previously been treated with drugs targeting CD47 or SIRPα2.I haven't had any cancer treatment in the last 2 weeks.I have a serious heart condition that is not under control.I have taken a pregnancy test recently and it was negative.I have had lung inflammation treated with steroids or have it now.I have taken a pregnancy test recently and it was negative.I am a man who can father a child and will use contraception during and 4 months after the study.I am on long-term immunosuppression for an autoimmune disorder.My Hodgkin lymphoma has returned or is not responding to treatment.I have HIV or hepatitis B/C with active virus replication.I have had another cancer, but it has been in complete remission for over a year, except for skin cancer or localized prostate cancer.My white blood cell count is healthy without needing medication in the last 3 weeks.My Hodgkin lymphoma has returned or is not responding to treatment.I have undergone at least two different treatments for my condition.I am 18 years old or older.I am 18 years old or older.My PET scan shows active cancer.I have not received a live vaccine in the last 30 days.My PET scan shows active cancer.I am not pregnant or breastfeeding.I needed more than 2 blood transfusions in the last month.
- Group 1: Magrolimab (Hu5F9 G4) and pembrolizumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What diseases or conditions has Magrolimab been clinically proven to ameliorate?
"Magrolimab is well-known for treating malignant neoplasms, but has also been used to address unresectable melanoma, microsatellite instability high syndrome and post-chemotherapy progression of illnesses."
Are there any existing reports on the efficacy of Magrolimab?
"Currently, there are 975 active clinical studies involving Magrolimab and 125 trials in the penultimate phase of development. Texas' Houston is a hub for this drug's research with numerous ongoing trials, while 36276 locations across the world have Magrolimab-related experiments running."
Are there still vacancies available to join this investigation?
"The trial is actively recruiting, as confirmed on clinicaltrials.gov. This investigation was initially advertised on June 21st 2022 and its details were updated most recently on the same date."
What is the current level of participation in this experiment?
"Affirmative. As indicated on the clinicaltrials.gov website, this research study was initially uploaded on June 21st 2022 and is currently accepting applicants to join in its endeavour. 24 participants are being sought out across a single site for recruitment."
What adverse effects have been associated with Magrolimab usage?
"Magrolimab is currently classified as a 2 on the safety scale due to its Phase 2 status, which implies there are data confirming it safe but not yet supportive of efficacy."
Share this study with friends
Copy Link
Messenger